NCT04937751 Markers of Infection and Resistance in Invasive Fusariosis
| NCT ID | NCT04937751 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central Hospital, Nancy, France |
| Condition | Fusariosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-07-19 |
| Primary Completion | 2028-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2023-07-19 with a primary completion date of 2028-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In recent decades, invasive fusarioses have been emerging fungal pathologies with high mortality. The prognosis depends on the speed of the diagnosis, but currently biological diagnosis is mainly based on fungal culture, no specific biomarker for this microorganism is available in current clinical practice. The genus Fusarium also shows reduced sensitivity to antifungals commonly used and recommended in clinical practice, such as voriconazole or amphotericin B. The main objective of this study is to describe the proportions of different fungal species in positive fungal cultures in patients with invasive fungal infection (IFI) or fungal keratitis. The secondary objectives are the description of the dosage of galactomannans, beta (1,3) -D-glucans and the rate of detection of DNA circulating in case / control groups for the 2 clinical forms studied. In patients with evidence of Fusarium wilt, the study will describe the distribution of the different minimum inhibitory concentrations (MIC) depending on whether or not different antifungals are taken, the vital status at 3 months, and the response or not to treatment. Finally, the presence of genetic markers will be described according to the groups of MIC values.
Eligibility Criteria
Inclusion Criteria: * Suspicion of invasive fungal infection involving the performance of a blood culture or a skin biopsy or diagnosis of keratitis involving the taking of a cornea sample * Fungal culture carried out on this sample * Person having been informed of the research and not having opposed the use of their data Exclusion Criteria: * Clinical diagnosis of superficial fusarium wilt (onychomycosis, etc.)
Frequently Asked Questions
Who can join the NCT04937751 clinical trial?
This trial is open to participants of all sexes, studying Fusariosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04937751 currently recruiting?
Yes, NCT04937751 is actively recruiting participants. Visit ClinicalTrials.gov or contact Central Hospital, Nancy, France to inquire about joining.
Where is the NCT04937751 trial being conducted?
This trial is being conducted at Vandœuvre-lès-Nancy, France.
Who is sponsoring the NCT04937751 clinical trial?
NCT04937751 is sponsored by Central Hospital, Nancy, France. The trial plans to enroll 150 participants.